oh, I'll take the "seed" money/sales...while new strategy hatches...
imo, they failed...and realized it before "re-launch"...but, who's to say?
so much for the "gloom & doom" from TEABAGA KTEAM!!!?!?!? LOLOL...PREDICTIONS: 1,279. RATE OF ENLIGHTENMENT: 2-3%. PREDICTIONS RESULTING IN PRO-SHORT ACTION: 17. RATE OF SUCCESS: 1.3%...at BEST?!!?!?!?
who cares about Endo....? surely, not me...they had their chance...by default, no less...and, basically, failed imo.
no longer at the MERCY OF FAILED PARTNER RELATIONSHIPS...NO ACQUISITION TO WAIT FOR (unless, of course, it's Vivus being acquired)...NO MORE WAIT!?!?!?!!? KTEAM DREAMS = NIGHTMARES!!!!?
what do you think I am saying...? Auxl & Endo were ineffective, imo, with wrong sales strategy, imo.
lol...denying it does not make it right. stendra works faster, right?
IMO, AUXL & ENDP did not do "BAGAS" any favors...will see what future holds...
Stendra better than Viagra/Cialis/Levitra/etc...
Q better than B & C...so, what's your beef, rubic?
stander rights being returned to Vivus...sales to ramp up soon?!?!!?
prexit not attributed to KTEAM2 "failure" efforts...SORRY, CLOWNTEAM!!!!
"nothing to report" by a company with TWO "BEST IN CLASS" DRUGS (imo)?!!?!?!?
call me a cheerleader if you want to go "there", but tell me where he has made an error in judgement or a misstep in decision-making...I, too, have watched the stock price, and believe imo that anything below $2 is a buying opportunity. but, you sound informed.
"We are excited to reacquire the U.S. and Canadian commercial rights for STENDRA. We appreciate Endo's efforts to build the STENDRA brand and understand their decision to focus their resources on BELBUCA™," said Seth Fischer, VIVUS Chief Executive Officer. "With STENDRA's 15 minute onset-of-action, efficacy, ability to be taken with food and alcohol, and safety profile, we remain confident in STENDRA's long-term prospects. We are in the process of evaluating ways for maximizing the value of STENDRA and expect to make an announcement by the end of the first quarter of 2016 with our decision. As part of this process, we are working closely with Auxilium to ensure a smooth transition of STENDRA back to VIVUS."
this is becoming comical...
when McBride says it's an experienced operator, I'm convinced. hasn't led us wrong yet.
patent portfolio for tobacco & marijuana at 200+, company cheap, AND possible licensing to other tobacco down the road?!?!? FDA testing lower nicotine...? do your own DD, but big tobacco should take this company out, imo.